On March 3, 2026, Aquestive Therapeutics, Inc. amended a Purchase and Sale Agreement, extending the marketing deadline to June 30, 2027, and issued a warrant for 375,000 shares at $4.00 each. They also secured a commitment to sell at least $5 million worth of stock within 90 days of the agreement.